Cargando…
Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
BACKGROUND: Intravesical Bacillus Calmette–Guérin (BCG) remains the standard adjuvant treatment for non-muscle invasive bladder cancer (NMIBC) following transurethral resection; however, BCG failure and related toxicities are common. OBJECTIVES: To compare the efficacy and toxicity of intravesical B...
Autores principales: | Prasanna, Thiru, Craft, Paul, Balasingam, Gayathri, Haxhimolla, Hodo, Pranavan, Ganes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673621/ https://www.ncbi.nlm.nih.gov/pubmed/29164059 http://dx.doi.org/10.3389/fonc.2017.00260 |
Ejemplares similares
-
Bladder Contracture – A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy
por: Garcia, Cindy, et al.
Publicado: (2015) -
Bacillus Calmette–Guerin intravesical instillation therapy-induced urothelial necrosis of the bladder and upper urinary tract
por: Kondo, Tsubasa, et al.
Publicado: (2022) -
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007) -
Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
por: D’Andrea, David, et al.
Publicado: (2019) -
Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer
por: Miyazaki, Masashi, et al.
Publicado: (2016)